Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.34 |
| ▸ | MAOA | P21397 | 12/20 | 0.34 |
| ▸ | MAOB | P27338 | 12/20 | 0.34 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | YWHAG | P61981 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1532971 | 0.78 | ALDH1A1 (0.33) | KDM1ACUL4AALDH1A1HPGDLMNA | |
| SCHEMBL1074533 | 0.77 | KDM1A (0.40) | KDM1AMAOAMAOBLMNAHTR2A | |
| Methane SCHEMBL16507862 | 0.75 | KDM1A (0.39) | KDM1AMAOAMAOBHTR2AHTR2C | |
| SCHEMBL4794111 | 0.74 | KDM1A (0.38) | KDM1AMAOAMAOBHTR2AHTR2C | |
| SCHEMBL5526874 | 0.74 | KDM1A (0.38) | KDM1AMAOAMAOBHTR2AHTR2C | |
| SCHEMBL6496498 | 0.74 | HTR2A (0.42) | KDM1AMAOAMAOBHTR2AHTR2C | |
| SCHEMBL16486982 | 0.73 | ALDH1A1 (0.35) | ALDH1A1HPGDLMNAKDM4EMEN1 | |
| SCHEMBL3480926 | 0.73 | KDM1A (0.35) | KDM1AMAOAMAOBALDH1A1HPGD | |
| SCHEMBL8407466 | 0.73 | HTR2A (0.33) | KDM1AHTR2AHTR2CHTR2B | |
| SCHEMBL727295 | 0.72 | CUL4A (0.30) | CUL4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8294974-B2 | Electrochromic material and electrochromic device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-10-23 | — | — | US | disclosed |
| US-20110235150-A1 | ELECTROCHROMIC MATERIAL AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-09-29 | — | — | US | disclosed |
| CN-101855203-A | F1F0Inhibitors of ATP synthase and related methods | UNIV MICHIGAN | 2010-10-06 | — | — | CN | disclosed |
| US-6495699-B2 | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | AGOURON PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | BENDER STEVEN L (US) | 2002-02-14 | — | — | US | disclosed |
| US-6306892-B1 | ENZYME INHIBITORS HETEROCYCLIC AMIDES | AGOURON PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| US-6174915-B1 | FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY | AGOURON PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6008243-A | AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0937042-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998017643-A1 | HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-04-30 | — | — | WO | disclosed |
| US-5239013-A | Nonlinear optically active polymers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| US-5216084-A | Nonlinear optically active polymers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0394027-A2 | Nonlinear optically active polymers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4952640-A | Nonlinear optically active polymers | MINNESOTA MINING AND MANUFACTURING CO. (US) | 1990-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110235150-A1 | ELECTROCHROMIC MATERIAL AND ELECTROCHROMIC DEVICE INCLUDING THE SAME | EPN1, RPS3A, RPS10 | KDM1A 284/4885MAOA 1252/4885MAOB 1085/4885 |
| US-20020019429-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use | MMP9, MMP2, MMP3 | KDM1A 439/4885MAOA 224/4885MAOB 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.